Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1476-1483

  Patel, Poulam M ^a   Suciu, Stefan ^b   Mortier, Laurent ^c   Kruit, Wim H ^d   Robert, Caroline ^e   Schadendorf, Dirk ^f   Trefzer, Uwe ^g   Punt, Cornelis J A ^h   Dummer, Reinhard ⁱ   Davidson, Neville ^j   Becker, Juergen ^k   Conry, Robert ^l   Thompson, John A ^m   Hwu, Wen Jen ⁿ   Engelen, Kristel ^b   Agarwala, Sanjiv S ^o   Keilholz, Ulrich ^g   Eggermont, Alexander M M ^e   Spatz, Alain ^p  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b EORTC DATA CENTER   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j BROOMFIELD HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m SEATTLE CANCER CARE ALLIANCE   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o St Lukes Cancer Centre   (United States)

^p MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Chemotherapy; Dacarbazine; Melanoma; Phase III; Stage IV; Temozolomide

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG INTOXICATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AREA UNDER CURVE; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; SAFETY; SKIN NEOPLASMS; TIME FACTORS;

EID: 79958783120     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.030     Document Type: Article

References (30)

1. E. de Vries, F.I. Bray, J.W. Coebergh, and D.M. Parkin Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia Int J Cancer 107 1 2003 119 126 (Pubitemid 37100095)
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. C.M. Balch, A.C. Buzaid, and S.J. Soong Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 2001 3635 3648 (Pubitemid 32786276)
4. A. Balch, S.J. Soong, and M.B. Atkins An evidence-based staging system for cutaneous melanoma CA Cancer J Clin 54 2004 131 149 (quiz 182-4) (Pubitemid 38812179)
5. A. Barth, L.A. Wanek, and D.L. Morton Prognostic factors in 1, 521 melanoma patients with distant metastases J Am Coll Surg 181 1995 193 201
6. O. Eton, S.S. Legha, and T.E. Moon Prognostic factors for survival of patients treated systemically for disseminated melanoma J Clin Oncol 16 1998 1103 1111 (Pubitemid 28108747)
7. P.B. Chapman, L.H. Einhorn, and M.L. Meyers Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 1999 2745 2751 (Pubitemid 29415231)
8. A.M. Eggermont, and J.M. Kirkwood Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40 12 2004 1825 1836 (Pubitemid 39036756)
9. M.F. Avril, S. Aamdal, and J.J. Grob Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 22 2004 1118 1125 (Pubitemid 41095046)
10. A.Y. Bedikian, M. Millward, and H. Pehamberger Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group J Clin Oncol 24 2006 4738 4745 (Pubitemid 46630937)
11. E.S. Newlands, M.F. Stevens, and S.R. Wedge Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1997 35 61 (Pubitemid 27273454)
12. E.S. Newlands, G.R. Blackledge, and J.A. Slack Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer 65 1992 287 291
13. M. Patel, C. McCully, and K. Godwin Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates J Neurooncol 61 2003 203 207 (Pubitemid 36342297)
14. C. Marzolini, L.A. Decosterd, and F. Shen Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration Cancer Chemother Pharmacol 42 1998 433 440 (Pubitemid 28465205)
15. C.D. Britten, E.K. Rowinsky, and S.D. Baker A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies Clin Cancer Res 5 1999 1629 1637 (Pubitemid 29334438)
16. C.S. Brock, E.S. Newlands, and S.R. Wedge Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res 58 1998 4363 4367 (Pubitemid 28450038)
17. N.M. Bleehen, E.S. Newlands, and S.M. Lee Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 1995 910 913
18. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 2000 158 166 (Pubitemid 30036349)
19. M.R. Middleton, S.M. Lee, and A. Arance O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study Int J Cancer 88 2000 469 473
20. W. Wick, M. Platten, and M. Weller New (alternative) temozolomide regimens for the treatment of glioma Neuro Oncol 11 2009 69 79
21. A.W. Tolcher, S.L. Gerson, and L. Denis Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 2003 1004 1011 (Pubitemid 36560766)
22. National Cancer Institute: Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. Bethesda, MD, National Cancer Institute. 1993. http://ctep.cancer.gov/ investigatorResources/docs/hndbk.pdf.
23. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Publication No. 48. Geneva, Switzerland, World Health Organization, 1979 http://whqlibdoc.who.int/offset/WHO-OFFSET-48.pdf.
24. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
25. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0, NCI. Bethesda, MD, National Cancer Institute. 2006. http://ctep.info.nih. gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
26. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 51 1975 103 115
27. J.D. Kalbfleisch, and R.L. Prentice The survival analysis of failure time data 2nd ed. 2002 Wiley Series in Probability and Statistics. Wiley Inter-Science New Jersey, USA
28. U. Keilholz, C.J. Punt, and Gore Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 23 27 2005 6747 6755 (Pubitemid 46190270)
29. H. Schmidt, S. Suciu, C.J. Punt American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951 Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial J Clin Oncol 25 12 2007 1562 1569 (Pubitemid 46733083)
30. S.S. Agarwala, J.M. Kirkwood, and M. Gore Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study J Clin Oncol 22 2004 2101 2107 (Pubitemid 41095143)